All In Biotech

Drug Trial Radar · NCT07796256

Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria

A Multicenter, Randomized, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Multiple Doses of SGB-9768 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Aug 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Suzhou Sanegene Bio Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-Label Phase II study to evaluate the efficacy and safety of multiple doses of SGB-9768 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • SGB-9768Drug

    SGB-9768 will be administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean LDH change from baselineTime frame: weeks 18-24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.